Photo of Tracy T. Batchelor,  MD, MPH

Tracy T. Batchelor, MD, MPH

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-8770
Fax: (617) 724-8769

Tracy T. Batchelor, MD, MPH

Massachusetts General Hospital


  • Giovanni Armenise - Harvard Professor of Neurology, Neurology, Harvard Medical School
  • Executive Director, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital



  • Member, Center Scientific Council

Research Abstract

My work involves the development of novel therapeutics for malignant primary brain tumors. Our investigations in glioblastoma emphasize the development of imaging and tumor markers of sensitivity and resistance to anti-angiogenic therapeutics in preclinical models and humans. We employ novel MRI and PET imaging techniques in order to define subpopulations of glioblastoma patients most likely to benefit from agents targeting vascular endothelial growth factor (VEGF). We are also involved in defining and exploiting alternative pro-angiogenic targets in order to augment and extend responses to anti-VEGF therapeutics. I am also involved in early phase human trials of targeted therapeutics in molecularly defined subsets of glioblastoma.

I have played central roles in defining the optimal diagnostic and treatment pathways for primary CNS diffuse large B-cell lymphoma (PCNSL). I co-founded the International PCNSL Collaborative Group more than a decade ago and I remain the chair of this organization of over 125 hematologists, neurologists and oncologists from more than 20 countries. In the setting of local, national and international studies we have established the currently recommended diagnostic evaluation for newly diagnosed PCNSL patients. I have also spearheaded key chemotherapy trials for PCNSL contributing to currently recommended treatment guidelines for PCNSL.



Powered by Harvard Catalyst
  • Betensky RA, Szymonifka J, Lee EQ, Nutt CL, Batchelor TT. Computationally simple analysis of matched, outcome-based studies of ordinal disease states. Stat Med 2015; 34:2514-27. PubMed
  • Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM. Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients. Transl Oncol 2015; 8:137-46. PubMed
  • Neagu MR, Gill CM, Batchelor TT, Brastianos PK. Genomic profiling of brain metastases: current knowledge and new frontiers. Chin Clin Oncol 2015; 4:22. PubMed
  • Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. 2015. PubMed
  • Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, Mikkelsen T, Purow BW, Muzikansky A, Ancukiewicz M, Huse JT, Ramkissoon S, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain RK, Batchelor TT, Ligon KL, Wen PY. A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res 2015. PubMed
  • Nayak L, Pentsova E, Batchelor TT. Primary CNS lymphoma and neurologic complications of hematologic malignancies. Continuum (Minneap Minn) 2015; 21:355-72. PubMed
  • Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 2015; 33:1197-213. PubMed
  • Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 2015; 84:280-6. PubMed
  • Shih HA, Sherman JC, Nachtigall LB, Colvin MK, Fullerton BC, Daartz J, Winrich BK, Batchelor TT, Thornton LT, Mancuso SM, Saums MK, Oh KS, Curry WT, Loeffler JS, Yeap BY. Proton therapy for low-grade gliomas: Results from a prospective trial. Cancer 2015. PubMed
  • Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. 2015. PubMed
  • Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT. Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J. Neurooncol. 2014. PubMed
  • Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J. Neurooncol. 2014. PubMed
  • Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res 2014; 20:5612-9. PubMed
  • Emblem KE, Farrar CT, Gerstner ER, Batchelor TT, Borra RJ, Rosen BR, Sorensen AG, Jain RK. Vessel calibre-a potential MRI biomarker of tumour response in clinical trials. Nat Rev Clin Oncol 2014; 11:566-584. PubMed
  • Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DA. Brain Tumor Cells in Circulation Are Enriched for Mesenchymal Gene Expression. 2014. PubMed
  • Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. 2014. PubMed
  • Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 2014. PubMed
  • Batchelor TT. Comment: Defining cure in primary CNS lymphoma. Neurology 2014; 82:1373. PubMed
  • Reuter M, Gerstner ER, Rapalino O, Batchelor TT, Rosen B, Fischl B. Impact of MRI head placement on glioma response assessment. J. Neurooncol. 2014. PubMed
  • Pinho MC, Polaskova P, Kalpathy-Cramer J, Jennings D, Emblem KE, Jain RK, Rosen BR, Wen PY, Sorensen AG, Batchelor TT, Gerstner ER. Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. Oncologist 2014; 19:75-81. PubMed
  • Forst DA, Nahed BV, Loeffler JS, Batchelor TT. Low-grade gliomas. Oncologist 2014; 19:403-13. PubMed
  • Shankar GM, Taylor-Weiner A, Lelic N, Jones RT, Kim JC, Francis JM, Abedalthagafi M, Borges LF, Coumans JV, Curry WT, Nahed BV, Shin JH, Paek SH, Park SH, Stewart C, Lawrence MS, Cibulskis K, Thorner AR, Van Hummelen P, Stemmer-Rachamimov AO, Batchelor TT, Carter SL, Hoang MP, Santagata S, Louis DN, Barker FG, Meyerson M, Getz G, Brastianos PK, Cahill DP. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Acta Neuropathol Commun 2015; 2:167. PubMed
  • Nayak L, Batchelor TT. Recent advances in treatment of primary central nervous system lymphoma. Curr Treat Options Oncol 2013; 14:539-52. PubMed
  • Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A 2013; 110:19059-64. PubMed
  • Taylor JW, Flanagan EP, O'Neill BP, Siegal T, Omuro A, Deangelis L, Baehring J, Nishikawa R, Pinto F, Chamberlain M, Hoang-Xuan K, Gonzalez-Aguilar A, Batchelor T, Blay JY, Korfel A, Betensky RA, Lopes MB, Schiff D. Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. Neurology 2013; 81:1690-6. PubMed
  • Ferreri AJ, Zucca E, Armitage J, Cavalli F, Batchelor TT. Ten years of international primary CNS lymphoma collaborative group studies. J Clin Oncol 2013; 31:3444-5. PubMed
  • Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013; 31:3212-8. PubMed
  • Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest 2013; 123:3659-63. PubMed
  • Emblem KE, Mouridsen K, Bjornerud A, Farrar CT, Jennings D, Borra RJ, Wen PY, Ivy P, Batchelor TT, Rosen BR, Jain RK, Sorensen AG. Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat Med 2013; 19:1178-83. PubMed
  • Batchelor TT. Flying solo: chemotherapy without radiation for primary CNS lymphoma. J Clin Oncol 2013; 31:3051-3. PubMed
  • Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. 2013; 15:1079-87. PubMed
  • Clark SW, Taylor J, Wang DL, Abramson JS, Batchelor TT. Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma. Neurology 2013; 81:93-4. PubMed
  • Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. 2013; 15:930-5. PubMed
  • Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. J Clin Oncol 2013; 31:e233-6. PubMed
  • Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Reply to B. Freidlin et al. J Clin Oncol 2013; 31:970-1. PubMed
  • Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J. Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 2012; 10:14-26. PubMed
  • Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. J. Neurooncol. 2012; 110:89-98. PubMed
  • Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol 2012; 30:3258-63. PubMed
  • Brastianos PK, Batchelor TT. Primary central nervous system lymphoma: overview of current treatment strategies. Hematol Oncol Clin North Am 2012; 26:897-916. PubMed
  • Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, Wang M, Wen PY, Ivy P, Batchelor TT, Jain RK. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012; 72:402-7. PubMed
  • Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012; 4:116ra4. PubMed
  • Mohapatra G, Engler DA, Starbuck KD, Kim JC, Bernay DC, Scangas GA, Rousseau A, Batchelor TT, Betensky RA, Louis DN. Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomas. Acta Neuropathol 2011; 121:529-43. PubMed
  • Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011; 76:929-30. PubMed
  • Jeyaretna DS, Curry WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR. Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol 2011; 29:e159-62. PubMed
  • Abla O, Weitzman S, Blay JY, O'Neill BP, Abrey LE, Neuwelt E, Doolittle ND, Baehring J, Pradhan K, Martin SE, Guerrera M, Shah S, Ghesquieres H, Silver M, Betensky RA, Batchelor T. Primary CNS lymphoma in children and adolescents: a descriptive analysis from the international primary CNS lymphoma collaborative group (IPCG). Clin Cancer Res 2011; 17:346-52. PubMed
  • Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011; 16:1589-99. PubMed
  • di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res 2011; 71:19-28. PubMed
  • Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelson T, Fisher J, Desideri S, He X, Grossman SA, . A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J. Neurooncol. 2010; 100:261-8. PubMed
  • Gerstner ER, Batchelor TT. Imaging and response criteria in gliomas. Curr Opin Oncol 2010; 22:598-603. PubMed
  • Kahn J, Loeffler JS, Niemierko A, Chiocca EA, Batchelor T, Chakravarti A. Long-Term Outcomes of Patients with Spinal Cord Gliomas Treated by Modern Conformal Radiation Techniques. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. A multi-institution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. 2010; 12:1071-7. PubMed
  • Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J. Neurooncol. 2010. PubMed
  • Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol. Neurotol. 2010; 31:1135-43. PubMed
  • Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY. Phase I Study of Vandetanib with Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma. Int J Radiat Oncol Biol Phys 2010; 78:85-90. PubMed
  • Brastianos PK, Batchelor TT. Vascular endothelial growth factor inhibitors in malignant gliomas. Target Oncol 2010; 5:167-74. PubMed
  • Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, Kuittinen O, Chamberlain MC, Roth P, Nemets A, Shalom E, Ben-Yehuda D, Siegal T, . Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood 2010; 115:5005-11. PubMed
  • Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28:2817-23. PubMed
  • Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. 2010; 12:603-7. PubMed
  • Gerstner ER, Chen PJ, Wen PY, Jain RK, Batchelor TT, Sorensen G. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. 2010; 12:466-72. PubMed
  • Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch Neurol 2010; 67:291-7. PubMed
  • Gerstner ER, Frosch MP, Batchelor TT. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010; 28:e91-3. PubMed
  • Brastianos PK, Batchelor TT. VEGF inhibitors in brain tumors. Clin Adv Hematol Oncol 2010; 7:753-60, 768. PubMed
  • Dietrich J, Wang D, Batchelor TT. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin Investig Drugs 2009; 18:1549-57. PubMed
  • Michaud DS, Holick CN, Batchelor TT, Giovannucci E, Hunter DJ. Prospective study of meat intake and dietary nitrates, nitrites, and nitrosamines and risk of adult glioma. Am J Clin Nutr 2009; 90:570-7. PubMed
  • Sorensen AG,Batchelor TT,Zhang WT,Chen PJ,Yeo P,Wang M,Jennings D,Wen PY,Lahdenranta J,Ancukiewicz M,di Tomaso E,Duda DG,Jain RK. A "Vascular Normalization Index" as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients. Cancer Res 2009; 69:5296-300. PubMed
  • Chi AS,Sorensen AG,Jain RK,Batchelor TT. Angiogenesis as a Therapeutic Target in Malignant Gliomas. Oncologist 2009; 14:621-36. PubMed
  • Jain RK,Duda DG,Willett CG,Sahani DV,Zhu AX,Loeffler JS,Batchelor TT,Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6:327-338. PubMed
  • Kamoun WS,Ley CD,Farrar CT,Duyverman AM,Lahdenranta J,Lacorre DA,Batchelor TT,di Tomaso E,Duda DG,Munn LL,Fukumura D,Sorensen AG,Jain RK. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27:2542-52. PubMed
  • Aghi MK,Batchelor TT,Louis DN,Barker FG 2nd,Curry WT Jr. Decreased rate of infection in glioblastoma patients with allelic loss of chromosome 10q. J Neurooncol 2009; 93:115-20. PubMed
  • Gerstner ER,Sorensen AG,Jain RK,Batchelor TT. Anti-vascular endothelial growth factor therapy for malignant glioma. Curr Neurol Neurosci Rep 2009; 9:254-62. PubMed
  • Zhu JJ,Gerstner ER,Engler DA,Mrugala MM,Nugent W,Nierenberg K,Hochberg FH,Betensky RA,Batchelor TT. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro-oncol 2008; 11:211-5. PubMed
  • Gerstner ER,Duda DG,di Tomaso E,Ryg PA,Loeffler JS,Sorensen AG,Ivy P,Jain RK,Batchelor TT. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009; 6:229-36. PubMed
  • Drappatz J,Wong ET,Schiff D,Kesari S,Batchelor TT,Doherty L,Lafrankie DC,Ramakrishna N,Weiss S,Smith ST,Ciampa A,Zimmerman J,Ostrowsky L,David K,Norden A,Barron L,Sceppa C,Black PM,Wen PY. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2008; 73:222-7. PubMed
  • Rubenstein JL,Shen A,Batchelor TT,Kadoch C,Treseler P,Shuman MA. Differential gene expression in central nervous system lymphoma. Blood 2009; 113:266-7; author reply 267-8. PubMed
  • Mrugala MM,Rubenstein JL,Ponzoni M,Batchelor TT. Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep 2008; 11:73-80. PubMed
  • Gerstner ER,Sorensen AG,Jain RK,Batchelor TT. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 2008; 21:728-35. PubMed
  • Sorensen AG,Batchelor TT,Wen PY,Zhang WT,Jain RK. Response criteria for glioma. Nat Clin Pract Oncol 2008; 5:634-44. PubMed
  • Gerstner ER,Abrey LE,Schiff D,Ferreri AJ,Lister A,Montoto S,Tsang R,Thiel E,Graus F,Behringer D,Illerhaus G,Weaver S,Wen P,Voloschin A,Harris NL,Batchelor TT. CNS Hodgkin lymphoma. Blood 2008; 112:1658-61. PubMed
  • Grossman SA,Carson KA,Phuphanich S,Batchelor T,Peereboom D,Nabors LB,Lesser G,Hausheer F,Supko JG. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas. Neuro-oncol 2008; 10:608-16. PubMed
  • Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-oncol 2008; 10:300-8. PubMed
  • Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 2008; 88:43-50. PubMed
  • Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 2008; 8:541-53. PubMed
  • Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro-oncol 2008; 10:190-8. PubMed
  • Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 2007; 111:1085-93. PubMed
  • Gerstner ER, Carson KA, Grossman SA, Batchelor TT. Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 2008; 70:401-2. PubMed
  • Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2007; 86:211-5. PubMed
  • Gerstner ER, Duda DG, di Tomaso E, Sorensen G, Jain RK, Batchelor TT. Antiangiogenic agents for the treatment of glioblastoma. Expert Opin Investig Drugs 2007; 16:1895-908. PubMed
  • Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8:610-22. PubMed
  • Drappatz J, Batchelor TT. Leptomeningeal Neoplasms. Curr Treat Options Neurol 2007; 9:283-293. PubMed
  • Correa D, Maron L, Harder H, Klein M, Armstrong C, Calabrese P, Bromberg J, Abrey L, Batchelor T, Schiff D. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007; 18:1145-51. PubMed
  • Kesari S, Schiff D, Doherty L, Gigas DC, Batchelor TT, Muzikansky A, O'neill A, Drappatz J, Chen-Plotkin AS, Ramakrishna N, Weiss SE, Levy B, Bradshaw J, Kracher J, Laforme A, Black PM, Folkman J, Kieran M, Wen PY. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro-oncol 2007; 9:354-63. PubMed
  • Eichler AF, Batchelor TT, Henson JW. Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate. Neuro-oncol 2007; 9:373-7. PubMed
  • Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007; 13:223-30. PubMed
  • Gerber DE, Grossman SA, Batchelor T, Ye X. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. Cancer Chemother Pharmacol 2006; 59:817-23. PubMed
  • Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT, Iafrate AJ, Louis DN. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res 2007; 13:2038-45. PubMed
  • Norden AD, Batchelor TT. Reversible posterior leukoencephalopathy syndrome. Onkologie 2007; 30:90-1. PubMed
  • Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83-95. PubMed
  • Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am 2006; 20:1337-61. PubMed
  • Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN, Nutt CL. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 2006; 65:1181-8. PubMed
  • Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res 2006; 12:5174-81. PubMed
  • Grier JT, Batchelor T. Low-grade gliomas in adults. Oncologist 2006; 11:681-93. PubMed
  • Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006; 107:3716-23. PubMed
  • Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Greenman C, Edkins S, Bignell G, Davies H, O'Meara S, Parker A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A, Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts C, Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G, Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN, Stratton MR, Futreal PA, Wooster R. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 2006; 66:3987-91. PubMed
  • Jahnke K, Korfel A, O'neill BP, Blay JY, Abrey LE, Martus P, Poortmans PM, Shenkier TN, Batchelor TT, Neuwelt EA, Raizer JJ, Schiff D, Pels H, Herrlinger U, Stein H, Thiel E. International study on low-grade primary central nervous system lymphoma. Ann Neurol 2006; 59:755-762. PubMed
  • Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006; 24:1281-8. PubMed
  • Eichler AF, Batchelor TT. Primary central nervous system lymphoma: presentation, diagnosis and staging. Neurosurg Focus 2006; 21:E15. PubMed
  • Shah GD, Kesari S, Xu R, Batchelor TT, O'Neill AM, Hochberg FH, Levy B, Bradshaw J, Wen PY. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-oncol 2006; 8:38-46. PubMed
  • Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10:5643-6. PubMed
  • Baehring JM, Batchelor TT. Diagnosis and management of neurolymphomatosis. Cancer J 2012; 18:463-8. PubMed
  • Gerstner ER, Yip S, Wang DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT Methylation is a Prognostic Biomarker in Elderly Patietns with Newly Diagnosed Glioblastoma Neurology 2009; 73:1509-1510.
  • Nguyen P, Chakravarti A, Batchelor T, Hochberg F, Loeffler J. Results of Whole-Brain Radiation as Salvage of Methotrexate Failure in Patients with Primary Central Nervous System Lymphoma. J Am Diet Assoc 2006.
  • Ferreri AJM, Abrey LE, Blay J-Y, Borisch B, Hochman J, Neuwelt EA, Yahalom J, Zucca E, Cavalli F, Armitage JO, Batchelor TT.. Management of primary central nervous system lymphoma - a summary statement from the 8th International Conference on Malignant Lymphoma. J Clin Oncol 2003; 21:2407-2414.
  • Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy P, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK.. Increased Perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cerdiranib and chemoradiation. Proc Natl Acad Sci U S A 2013; 110:19059-19064.